Candel's Prostate Cancer Therapy Shows Durable Immune Remodeling Two Years Post-Treatment
CADL has more than doubled off its 52-week low of $4.35.
Summary
Candel presented new biomarker data at ASTRO 2026 showing aglatimagene besadenovec plus radiation significantly increased intratumoral lymphocyte infiltration and remodeled the tumor microenvironment compared to placebo in intermediate-risk localized prostate cancer, with effects persisting more than two years after treatment and durable local and systemic immune activation. The analysis of 622 pre-treatment and 427 post-treatment biopsies found significantly greater lymphocyte-tumor engagement in residual tumors (p=0.003). A Phase 3 subgroup showed a 41% lower risk of recurrence or death. This mechanistic evidence supports the previously reported clinical benefit of improved disease-free survival and pathologic response, strengthening the case for the planned BLA submission. The company's cash runway extends into Q1 2028, providing ample time for regulatory filing and potential commercialization.
At the time of this announcement, CADL was trading at $10.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $832.5M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.